Targeting XIAP Bypasses Bcl-2-Mediated Resistance to TRAIL and Cooperates with TRAIL to Suppress Pancreatic Cancer Growth In vitro and In vivo
about
Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor α-induced necroptosisThe Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancerAn intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI)Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosisIdentification of miRNA-7 by genome-wide analysis as a critical sensitizer for TRAIL-induced apoptosis in glioblastoma cells.XIAP is not required for human tumor cell survival in the absence of an exogenous death signalCellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitmentSmac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancerHDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.Hedgehog inhibition promotes a switch from Type II to Type I cell death receptor signaling in cancer cellsImplementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations.Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and BortezomibDihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5TRAIL treatment provokes mutations in surviving cells.TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.Active targeting of mesoporous silica drug carriers enhances γ-secretase inhibitor efficacy in an in vivo model for breast cancer.Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatmentPancreatic ductal adenocarcinoma: a review of immunologic aspects.The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skinTargeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.Blockade of Inhibitors of Apoptosis Proteins in Combination with Conventional Chemotherapy Leads to Synergistic Antitumor Activity in Medulloblastoma and Cancer Stem-Like Cells.DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeuticsIdentification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs.CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancerResistance to TRAIL in non-transformed cells is due to multiple redundant pathways.Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effectsIAP antagonists sensitize murine osteosarcoma cells to killing by TNFαApoptosis pathways and their therapeutic exploitation in pancreatic cancer.Combined modality therapy with TRAIL or agonistic death receptor antibodies.Inhibitor of apoptosis proteins: fascinating biology leads to attractive tumor therapeutic targets.Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies.Concise review: genetically engineered stem cell therapy targeting angiogenesis and tumor stroma in gastrointestinal malignancy.Differential role of RIP1 in Smac mimetic-mediated chemosensitization of neuroblastoma cells.Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB.High-resolution MRI analysis of breast cancer xenograft on the chick chorioallantoic membrane.AD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L.Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cellsCell death-independent activities of the death receptors CD95, TRAILR1, and TRAILR2.ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells.
P2860
Q24294685-F4EFC511-B9BF-465C-9729-2429E92A6158Q28468300-86CCED6A-CF1B-40EA-8A25-198B1EB21873Q28485864-E0FA122D-ADCA-4C4A-B76A-C24C1F1B50C3Q28729017-F6D7E59A-B855-47A1-9A8F-D7F16B1B3173Q30854013-6D16F1AF-B6E1-4963-9FDA-0718A722B6BCQ33523404-AED2552D-1155-4F02-B92E-8D453983C453Q33589801-9BC34C43-72FE-4EDC-97C3-A8CDC35E9A1FQ33767013-74A0CF87-A076-48B6-8367-48D39A524E1AQ33842416-FE5E170C-9CEA-4D0B-A8C1-EA72A4549477Q33869744-31B12D8C-AAC4-42EC-985E-9CCB3FD42E3CQ33897223-6981CF38-D549-485C-B639-5176AEB674E5Q33906039-05A7CA49-B833-4C9F-A6C0-9B9751D93D52Q34292461-002DA5E3-0CA2-4DD5-8640-E2D33E90D45EQ34383454-BEACD9AD-8AB0-4FFB-A3C8-D03178DEB779Q34557885-FE4A0277-32A9-4595-B185-A85C14C72ADBQ34881011-6CC99452-5D82-4C3A-9BA5-480A7A8CB73DQ34970050-DAF9A4BC-2F60-4541-9CE0-A5CDA5760CD3Q35870682-7C47BA17-1D0A-413B-8469-5DF02419D305Q35966223-1396B4BC-403F-4A7E-81A1-0640068F2701Q36049901-C4F86BAB-74B5-40F4-9078-7E954DC32353Q36106864-FCD8FA8C-6DAA-48C2-9E98-7A1F220CF956Q36215003-F6250B1B-42BA-48A4-B9A4-E89006397F0CQ36501732-4AFAADD9-2A4B-4F78-BB68-9E9F87C45E37Q36751562-0586BA06-57F2-4077-9951-BA21762EBA87Q37049583-5E56E6E5-DCA7-4298-955C-12E1290022B2Q37061991-EB34CC9C-D58A-4053-BD66-0FE846151056Q37073589-228C5D40-CB51-4318-A3E7-D9C5B5CDD7CAQ37376164-860BB850-78BA-470C-8CAA-92EDE5E2F6AAQ37453523-55DD72C2-AA53-45FD-AD20-61E294EAC7B9Q37832083-DD5156E6-8170-4FF3-8A80-3BB08988509AQ37875078-633584EB-2746-4D2F-8E6E-C01DA1A1BBB2Q37974461-832040CF-E35C-45F5-AE18-372A636712E2Q38058289-2D7D6F7D-95C4-4079-A504-4FD112377872Q38310891-45C251C9-0857-43DC-886C-89882CA5EA75Q38351517-6509DA2A-FE8B-4684-BDFC-B29495803B1AQ38906566-F7CC8FD5-6036-4ECC-A135-A340BE3BFAE1Q38960411-98243221-ABB6-4FBF-8892-E810964BA393Q39011040-26889843-3D08-4E2E-A8D7-947A42ECAE2CQ39013916-343BC205-3BEC-44FE-8D97-48B3211E646EQ39236559-426A7810-0E55-40A1-9AB8-88806C7E2516
P2860
Targeting XIAP Bypasses Bcl-2-Mediated Resistance to TRAIL and Cooperates with TRAIL to Suppress Pancreatic Cancer Growth In vitro and In vivo
description
im Oktober 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 October 2008
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2008
@uk
name
Targeting XIAP Bypasses Bcl-2- ...... er Growth In vitro and In vivo
@en
Targeting XIAP Bypasses Bcl-2- ...... er Growth In vitro and In vivo
@nl
type
label
Targeting XIAP Bypasses Bcl-2- ...... er Growth In vitro and In vivo
@en
Targeting XIAP Bypasses Bcl-2- ...... er Growth In vitro and In vivo
@nl
prefLabel
Targeting XIAP Bypasses Bcl-2- ...... er Growth In vitro and In vivo
@en
Targeting XIAP Bypasses Bcl-2- ...... er Growth In vitro and In vivo
@nl
P2093
P50
P1433
P1476
Targeting XIAP bypasses Bcl-2- ...... er growth in vitro and in vivo
@en
P2093
Dominic Stadel
Felicitas Genze
Henning Walczak
Jürgen E Gschwend
Marjana Jovanovic
Meike Vogler
Thomas Simmet
P304
P356
10.1158/0008-5472.CAN-08-1296
P407
P577
2008-10-01T00:00:00Z